{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:29:02Z","timestamp":1785587342255,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Research & Clinical Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.orcp.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:39:41Z","timestamp":1768538381000},"page":"2-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8445-778X","authenticated-orcid":false,"given":"Ahmed Samy","family":"Badran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrhman","family":"Helal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim Samir","family":"Shata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Ayesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.orcp.2026.01.002_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/HIV.S14561","article-title":"Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy","author":"Bedimo","year":"2011","journal-title":"HIV\/AIDS Res Palliat Care"},{"key":"10.1016\/j.orcp.2026.01.002_bib2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1742-1241.2007.01385.x","article-title":"Long-term complications of antiretroviral therapy: lipoatrophy","volume":"61","author":"Waters","year":"2007","journal-title":"Int J Clin Pr"},{"key":"10.1016\/j.orcp.2026.01.002_bib3","first-page":"126","article-title":"Disorders of body fat distribution in HIV-1-infected patients","volume":"11","author":"Moreno","year":"2009","journal-title":"AIDS Rev"},{"key":"10.1016\/j.orcp.2026.01.002_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/apc.2008.0067","article-title":"Treatment options for HIV-associated central fat accumulation","volume":"23","author":"Cofrancesco","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.orcp.2026.01.002_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jc.2004-1342","article-title":"Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy","volume":"90","author":"Koutkia","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.orcp.2026.01.002_bib6","first-page":"504","article-title":"Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy","volume":"86","author":"Rietschel","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.orcp.2026.01.002_bib7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/QAI.0b013e31804a7f68","article-title":"Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy","volume":"45","author":"Grunfeld","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.orcp.2026.01.002_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00126334-200403010-00004","article-title":"Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients","volume":"35","author":"Kotler","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.orcp.2026.01.002_bib9","unstructured":"US Food and Drug Administration. EGRIFTA (tesamorelin for injection) prescribing information, \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022505s000lbl.pd\u3009; 2010. [accessed January 8, 2026]."},{"key":"10.1016\/j.orcp.2026.01.002_bib10","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1016\/S2352-3018(19)30338-8","article-title":"Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial","volume":"6","author":"Stanley","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.orcp.2026.01.002_bib11","series-title":"Cochrane Handbok for Systematic Reviews of Interventions","author":"Higgins","year":"2024"},{"key":"10.1016\/j.orcp.2026.01.002_bib12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.orcp.2026.01.002_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5195\/jmla.2017.111","article-title":"Reviewing retrieved references for inclusion in systematic reviews using EndNote","volume":"105","author":"Bramer","year":"2017","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.orcp.2026.01.002_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.orcp.2026.01.002_bib15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.orcp.2026.01.002_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.orcp.2026.01.002_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.orcp.2026.01.002_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.orcp.2026.01.002_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.orcp.2026.01.002_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.orcp.2026.01.002_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.orcp.2026.01.002_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jama.2014.8334","article-title":"Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation","volume":"312","author":"Stanley","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.orcp.2026.01.002_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","article-title":"Effects of Tesamorelin, a Growth Hormone\u2013Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension","volume":"53","author":"Falutz","year":"2010","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.orcp.2026.01.002_bib24","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMoa072375","article-title":"Metabolic Effects of a Growth Hormone\u2013Releasing Factor in Patients with HIV","volume":"357","author":"Falutz","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.orcp.2026.01.002_bib25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/01.aids.0000180099.35146.30","article-title":"A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation","volume":"19","author":"Falutz","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.orcp.2026.01.002_bib26","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/infdis\/jiaf012","article-title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","volume":"231","author":"Ellis","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.orcp.2026.01.002_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.metabol.2010.09.011","article-title":"Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment","volume":"60","author":"Magkos","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.orcp.2026.01.002_bib28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.asj.2008.04.009","article-title":"Cofrancesco J. Lipodystrophy in the patient with HIV: social, psychological, and treatment considerations","volume":"28","author":"Peterson","year":"2008","journal-title":"Aesthetic Surg J"},{"key":"10.1016\/j.orcp.2026.01.002_bib29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1210\/clinem\/dgad604","article-title":"Characteristics of Abdominal Visceral Adipose Tissue, Metabolic Health and the Gut Microbiome in Adults","volume":"109","author":"U-Din","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.orcp.2026.01.002_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/eem.10.83","article-title":"Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy","volume":"6","author":"Mateo","year":"2011","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.orcp.2026.01.002_bib31","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1210\/clinem\/dgac079","article-title":"Approach to the Patient With Lipodystrophy","volume":"107","author":"Fourman","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.orcp.2026.01.002_bib32","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1093\/ofid\/ofz360.426","article-title":"353. A comparison study of prevalence and risk factors for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) by transient elastography (TE) in HIV-infected patients","volume":"6","author":"Choe","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.orcp.2026.01.002_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-14-0337","article-title":"Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs","volume":"171","author":"Araujo","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.orcp.2026.01.002_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QCO.0b013e3283420eef","article-title":"Pathogenesis and treatment of HIV lipohypertrophy","volume":"24","author":"Leung","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.orcp.2026.01.002_bib35","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/cid\/cis251","article-title":"Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin","volume":"54","author":"Stanley","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.orcp.2026.01.002_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00514","article-title":"Insulin resistance in HIV-patients: causes and consequences","volume":"9","author":"Pedro","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.orcp.2026.01.002_bib37","doi-asserted-by":"crossref","unstructured":"Falutz J., Allas S., Mamputu J., Potvin D., Kotler D., Somero M., et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation 2008. https:\/\/doi.org\/10.1097\/QAD.0b013e32830a5058.","DOI":"10.1097\/QAD.0b013e32830a5058"}],"container-title":["Obesity Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X26000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X26000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:14:20Z","timestamp":1770657260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871403X26000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1871403X26000025"],"URL":"https:\/\/doi.org\/10.1016\/j.orcp.2026.01.002","relation":{},"ISSN":["1871-403X"],"issn-type":[{"value":"1871-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Obesity Research & Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.orcp.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}